Greiner Bio-One acquires 3D Cell Culture Technology assets from Nano3D Biosciences, Inc.

Greiner Bio-One acquires 3D Cell Culture Technology assets from Nano3D Biosciences, Inc.

Human mesenchymal stem cell spheroid differentiated to chondrocyte lineage (Source: Greiner Bio-One)

Frickenhausen, May 14, 2018 – Greiner Bio-One North America, Inc. has acquired 3D Cell Culture Technology previously owned by Nano3D Biosciences, Inc. As an international distributor of these products since 2016, Greiner Bio-One has now taken the initiative to become a premier provider of this technology worldwide. Magnetic 3D cell culture has become a disruptive technology in the research marketplace by offering an improved method for growing cells and driving results in new pathways to disease treatment and prevention.

Heinz Schmid, CEO of Greiner Bio-One BioScience commented on this strategic acquisition: „The potential for growth in the 3D cell culture market is amazingly vast with laboratories and research facilities utilising this new technology daily to find cures for disease and improve the existing cell culture methodology. The acquisition of a magnetic 3D cell culture technology is just one of Greiner Bio-One’s ongoing efforts to advance scientific research and improve health, while providing researchers access to the best products.“

Nano3D Biosciences, Inc. President and Chief Scientific Officer, Glauco Souza: „We are delighted to have completed this acquisition with Greiner Bio-One. The synergy between Nano3D’s technology and Greiner Bio-One’s innovation in tissue culture makes this an excellent match to further advance magnetic 3D cell culture.“

About 3D cell culture technology:

Magnetic 3D cell culture is an innovative technology that allows for the magnetisation of cells that can then be aggregated through levitation or bioprinted to form a structurally and biologically representative 3D model in vitro. This is a crucial improvement over previously used cell culture methods due to its ability to better recreate cell growth and behaviour as it would be found in the body.
The CELLSTAR cell culture vessels with cell-repellent surface from Greiner Bio-One are ideal for cultivating cells to form three-dimensional structures. Outstanding results can be achieved, particularly when they are used in combination with the technology from Nano3D Biosciences.

Watch our video about magnetic 3D bioprinting of spheroids:
https://youtu.be/3QacNpXAOyk

150 years of Greiner!
In 2018, the Greiner Group is celebrating its 150th anniversary. What began in Nürtingen in 1868 with the foundation of a small general store by Carl Albert Greiner and his wife Emilie is today a globally successful family business with over 10,000 employees in 34 countries: https://www.youtube.com/watch?v=0F5DQhxatbs&feature=youtu.be

Greiner Bio-One International GmbH
Greiner Bio-One specialises in the development, production and distribution of high-quality plastic laboratory products. The company is a technology partner for hospitals, laboratories, universities, research institutes, and the diagnostic, pharmaceutical and biotechnology industries. Greiner Bio-One is split into three divisions – Preanalytics, BioScience and Sterilisation. IAs an Original Equipment Manufacturer (OEM), Greiner Bio-One provides individual solutions in the area of custom-made design developments and production processes for the life sciences and medical sectors. In 2017, Greiner Bio-One International GmbH generated a turnover of 473 million euros and had over 2,200 employees, 26 subsidiaries and numerous distribution partners in over 100 countries. Greiner Bio-One is part of Greiner Holding, which is based in Kremsmünster (Austria).

Greiner Bio-One BioScience Division
The BioScience division of Greiner Bio-One ranks among the leading providers of specialised products for the cultivation and analysis of cell and tissue cultures. Drawing on decades of experience with cryogenic sample storage, Greiner Bio-One also offers solutions for automated storage systems in biobanks. In addition, we continue to utilise our expertise in the development and production of microplates for high-throughput screening, thereby allowing extremely fast and efficient drug screening for both industrial and research applications. The entire development, manufacturing and sales operations are controlled from the German headquarters of the BioScience division in Frickenhausen.

Company-Contact
Greiner Bio-One GmbH
Simone Schafstein & Sylvia Bauer
Maybachstraße 2
72636 Frickenhausen
Phone: 0049-7022-948 0
Fax: 0049-7022-948-514
E-Mail: marketing@de.gbo.com
Url: https://www.gbo.com/en_DE.html

Press
Zeeb Kommunikation GmbH
Anja Pätzold
Hohenheimer Straße 58a
70184 Stuttgart
Phone: 0711-60 70 719
E-Mail: info@zeeb.info
Url: http://www.zeeb-kommunikation.de

Related posts